Overall, these discoveries indicate that RGS16 has a critical effect in breast cancer progression through allelic analysis, δEF1 family protein inhibition and GPCR-independent pathways, demonstrating that RGS16 may be a novel therapeutic target in breast cancer. This evidence concerns the gene RGS16 and breast carcinoma.